

VOTING RESULTS AND RESOLUTIONS OF THE ANNUAL GENERAL MEETING OF REDCARE PHARMACY N.V. HELD AS A HYBRID MEETING ON 17 APRIL 2024

A total of 12,684,566 shares were represented at the annual general meeting of Redcare Pharmacy N.V. (the "**Company**"), representing an equal number of votes to be exercised in respect of each of the voting items listed below. This represents 62.36% of the total issued and outstanding shares on the record date for the 2024 annual general meeting (i.e. on 20 March 2024), which amounted to 20,342,486 shares in bearer form. Percentages have been rounded.

Agenda item	Description	For	%	Against	%	Abstain	Percentage of the total issued and outstanding share capital ¹
2.b.	Remuneration report for the financial year 2023 ²	12,322,404	97,15	362,132	2,85	30	62,35
3.b.	Adoption of the financial statements for the financial year 2023	12,676,574	100	0	0	7,992	62,32
3.d.	Proposal to allocate the results of the financial year 2023	12,684,536	100	0	0	30	62,35
4.a.	Discharge from liability of all members of the managing board for the performance of their duties during the past financial year	12,667,384	99,96	5.173	0,04	12,009	62,3
4.b.	Discharge from liability of all members of the supervisory board for the performance of their duties during the past financial year	12,667,384	99,96	5.173	0,04	12,009	62,3
5.a.	Re-appointment of Mazars Accountants N.V. as external auditor of the Company to audit the financial statements of the Company for the financial year ending 31 December 2024	12,684,536	100	0	0	30	62,35
6.a.	Re-appointment of Mr. Björn Söder as a member of the supervisory board for an additional term of two years	12,030,852	94,85	653,684	5,15	30	62,35
7.a.	Final discharge from liability of Mr. Stephan Weber for the performance of his duties as a member of the managing board	12,666,830	99,95	5,727	0,05	12,009	62,3

¹ Percentage of the total number of votes for and against in relation to the total issued and outstanding share capital.

² Shareholders who provided a positive advice, voted "for". Shareholders who voted "against", provided a negative advice with respect to the Company's remuneration report for the financial year 2023. The results of the vote on this agenda item counts as an advisory, non-binding, vote.

Agenda item	Description	For	%	Against	%	Abstain	Percentage of the total issued and outstanding share capital ¹
7.b.	Final discharge from liability of Mr. Marc Fischer for the performance of his duties as a member of the managing board	12,666,830	99,95	5,727	0,05	12,009	62,3
7.c.	Re-appointment of Mr. Jasper Eenhorst as a member of the managing board and CFO of the Company for an additional term of four years	12,582,920	99,21	100,680	0,79	966	62,35
7.d.	Appointment of Mr. Dirk Brüse as a member of the managing board and CCO of the Company for a term of four years	12,582,920	99,21	100,680	0,79	966	62,35
7.e.	Appointment of Mr. Lode Fastré as a member of the managing board and CIO of the Company for a term of four years	12,582,920	99,21	100,680	0,79	966	62,35
8.a.	Extension of the exercise period for outstanding stock options granted under the 2020 stock option plan for the members of the managing board (as amended in 2022) to Mr. Weber and Mr. Fischer from 17 October 2024 until 1 October 2026, in connection with their continued advisory role at the Company	9,483,736	74,77	3,200,800	25,23	30	62,35
9.a.	Designation of the managing board as the corporate body authorised to issue shares and/or grant rights to acquire shares up to a maximum of 20%, and as the corporate body authorised to restrict or exclude the pre-emptive rights upon the issue of shares and/or the granting of rights to acquire shares for a period of five years, each subject to certain conditions and revocation of the current designation of the managing board	8,340,550	65,75	4,343,986	34,25	30	62,35
9.b.	Designation of the managing board as the corporate body authorised to grant (rights to acquire) shares under, pursuant to and in connection with the 2019 ESOP for the calendar year 2024	12,282,187	96,83	402,349	3,17	30	62,35
9.c.	Designation of the supervisory board as the corporate body authorised to grant (rights to acquire) shares under, pursuant to and in connection with the 2023 stock option plan for the members of the managing board for a period of 24 months	12,488,691	98,46	195,845	1,54	30	62,35
10.a.	Designation of the managing board as the corporate body authorised to repurchase shares in the Company's own share capital up to a maximum of 10% for a period of 18 months	12,676,080	100	0	0	8,486	62,31

Agenda item	Description	For	%	Against	%	Abstain	Percentage of the total issued and outstanding share capital¹
11.a.	Amendment of the Company's remuneration policy for members of the supervisory board	12,684,536	100	0	0	30	62,35